TY - JOUR
T1 - Concern about malignancy contributes to the psychosocial toll of dermatomyositis
AU - Helm, M. F.
AU - Bazewicz, C. G.
AU - Butt, M.
AU - Washington, A.
AU - Shumaker, K.
AU - Foulke, G. T.
N1 - Funding Information:
This work was supported by the Use of REDCap through Penn State is supported by NIH/NCATS Grant Number UL1 TR000127 and UL1 TR002014 through The Penn State Clinical & Translational Research Institute, Pennsylvania State University CTSA [Use of REDCap through Penn State is supported by N]. We are grateful to our colleagues at Penn State Dermatology for their help in recruiting patients. The use of REDCap through Penn State Clinical and Translational Research Institute is supported by the NIH/NCATS [grant numbers UL1 TR000127 and UL1 TR002014]
Funding Information:
The use of REDCap through Penn State Clinical and Translational Research Institute is supported by the NIH/NCATS [grant numbers UL1 TR000127 and UL1 TR002014]
Publisher Copyright:
© 2021 Informa Healthcare on license from Scandinavian Rheumatology Research Foundation.
PY - 2021
Y1 - 2021
N2 - Objective: Dermatomyositis (DM) is associated with increased morbidity and mortality, decreased quality of life, and an increased incidence of psychiatric illness. We performed a pilot study to investigate whether concern about malignancy contributes to the psychosocial toll of DM. Method: Patients with a recent DM diagnosis at our institution between 2013 and 2018 and no history of DM-associated malignancy completed standardized questionnaires and a novel survey generated by our group, and participated in focus groups. Results: Seventeen patients (14 females and three males) completed the surveys. The mean Dermatology Life Quality Index (DLQI) score was 2.75. The mean score on the Patient Health Questionnaire-9 (PHQ-9) was 5.35, with a range of 0–20. Our independent DM-specific questionnaire revealed a mean of 17.41 (range 2–40). Conclusion: Concern about the increased risk of malignancy contributes to the psychosocial toll of DM. Individual impacts are highly variable and patient specific. Clinicians should assess for depression and anxiety in patients with DM, understanding that concern for malignancy adds to the total psychosocial burden in some patients.
AB - Objective: Dermatomyositis (DM) is associated with increased morbidity and mortality, decreased quality of life, and an increased incidence of psychiatric illness. We performed a pilot study to investigate whether concern about malignancy contributes to the psychosocial toll of DM. Method: Patients with a recent DM diagnosis at our institution between 2013 and 2018 and no history of DM-associated malignancy completed standardized questionnaires and a novel survey generated by our group, and participated in focus groups. Results: Seventeen patients (14 females and three males) completed the surveys. The mean Dermatology Life Quality Index (DLQI) score was 2.75. The mean score on the Patient Health Questionnaire-9 (PHQ-9) was 5.35, with a range of 0–20. Our independent DM-specific questionnaire revealed a mean of 17.41 (range 2–40). Conclusion: Concern about the increased risk of malignancy contributes to the psychosocial toll of DM. Individual impacts are highly variable and patient specific. Clinicians should assess for depression and anxiety in patients with DM, understanding that concern for malignancy adds to the total psychosocial burden in some patients.
UR - http://www.scopus.com/inward/record.url?scp=85099406288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099406288&partnerID=8YFLogxK
U2 - 10.1080/03009742.2020.1843706
DO - 10.1080/03009742.2020.1843706
M3 - Article
C2 - 33432833
AN - SCOPUS:85099406288
VL - 50
SP - 227
EP - 230
JO - Scandinavian Journal of Rheumatology
JF - Scandinavian Journal of Rheumatology
SN - 0300-9742
IS - 3
ER -